| Name | Lonidamine |
| Description | Lonidamine (Diclondazolic Acid) is an indazole carboxylic acid derivative, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). |
| In vitro | In mice carrying glioma tumors, Lonidamine (160 mg/kg) effectively reduced tumor growth. |
| In vivo | In both normal and tumor cells, Lonidamine reduces oxygen consumption while augmenting aerobic glycolysis in normal cells, thereby inhibiting aerobic glycolysis in tumor cells. The compound induces apoptosis at a concentration of 50 mg/ml in resistant cell lines, including the human breast cancer cell line MCF-7 ADR(r) and the LB9 multiform glioblastoma cell line, which exhibit resistance to doxorubicin and nitrosourea. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.23 mM), Sonication is recommended. DMSO : 250 mg/mL (778.43 mM), Sonication is recommended. Ethanol : 1.6 mg/mL (4.98 mM), Sonication is recommended.
|
| Keywords | pulmonary fibrosis | MitochondrialMetabolism | Mitochondrial Metabolism | mitochondrial complex | Mitochondrial | lung fibrosis | Lonidamine | lactate | Inhibitor | inhibit | Hexokinase | H2030BrM3 | Apoptosis | AF-1890 | AF 1890 | A549 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Hydroxychloroquine | Metronidazole | 2-Amino-2-methyl-1-propanol | Doxycycline | Fenpyroximate | Formamide | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |